TuisCORT • NASDAQ
add
Corcept Therapeutics Inc
Vorige sluiting
$85,31
Dagwisseling
$85,06 - $87,50
Jaarwisseling
$49,00 - $117,33
Markkapitalisasie
9,17 mjd USD
Gemiddelde volume
694,01 k
P/V-verhouding
120,82
Dividend-opbrengs
-
Primêre beurs
NASDAQ
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Sep. 2025info | J/J-verandering |
|---|---|---|
Inkomste | 207,64 m | 13,75% |
Bedryfskoste | 192,82 m | 44,89% |
Netto inkomste | 19,67 m | -58,34% |
Netto winsgrens | 9,47 | -63,38% |
Wins per aandeel | 0,16 | -60,98% |
EBITDA | 10,51 m | -77,60% |
Effektiewe belastingkoers | -29,03% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Sep. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 421,68 m | 10,87% |
Totale bates | 823,61 m | 5,02% |
Totale aanspreeklikheid | 191,70 m | 31,83% |
Totale ekwiteit | 631,90 m | — |
Uitstaande aandele | 105,19 m | — |
Prys om te bespreek | 14,19 | — |
Opbrengs op bates | 3,14% | — |
Opbrengs op kapitaal | 3,99% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Sep. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | 19,67 m | -58,34% |
Kontant van bedrywe | 54,48 m | -25,67% |
Kontant van beleggings | 14,64 m | 133,26% |
Kontant van finansiering | -46,41 m | -120,05% |
Netto kontantverandering | 22,39 m | 157,36% |
Beskikbare kontantvloei | 38,75 m | -44,81% |
Meer oor
Corcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. Corcept has focused on the adverse effects of excess cortisol, studying new compounds that may mitigate those effects. Its executive team is headed by CEO, president and director Joseph K. Belanoff, MD. Wikipedia
Gestig
13 Mei 1998
Webwerf
Werknemers
500
